RT Journal Article
SR Electronic
T1 Multivariate, Multi-omic Analysis in 799,429 Individuals Identifies 134 Loci Associated with Somatoform Traits
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.29.24310991
DO 10.1101/2024.07.29.24310991
A1 Davis, Christal N.
A1 Toikumo, Sylvanus
A1 Hatoum, Alexander S.
A1 Khan, Yousef
A1 Pham, Benjamin K.
A1 Pakala, Shreya R.
A1 Feuer, Kyra L.
A1 Gelernter, Joel
A1 Sanchez-Roige, Sandra
A1 Kember, Rachel L.
A1 Kranzler, Henry R.
YR 2024
UL http://medrxiv.org/content/early/2024/07/29/2024.07.29.24310991.abstract
AB Somatoform traits, which manifest as persistent physical symptoms without a clear medical cause, are prevalent and pose challenges to clinical practice. Understanding the genetic basis of these disorders could improve diagnostic and therapeutic approaches. With publicly available summary statistics, we conducted a multivariate genome-wide association study (GWAS) and multi-omic analysis of four somatoform traits—fatigue, irritable bowel syndrome, pain intensity, and health satisfaction—in 799,429 individuals genetically similar to Europeans. Using genomic structural equation modeling, GWAS identified 134 loci significantly associated with a somatoform common factor, including 44 loci not significant in the input GWAS and 8 novel loci for somatoform traits. Gene-property analyses highlighted an enrichment of genes involved in synaptic transmission and enriched gene expression in 12 brain tissues. Six genes, including members of the CD300 family, had putatively causal effects mediated by protein abundance. There was substantial polygenic overlap (76-83%) between the somatoform and externalizing, internalizing, and general psychopathology factors. Somatoform polygenic scores were associated most strongly with obesity, Type 2 diabetes, tobacco use disorder, and mood/anxiety disorders in independent biobanks. Drug repurposing analyses suggested potential therapeutic targets, including MEK inhibitors. Mendelian randomization indicated potentially protective effects of gut microbiota, including Ruminococcus bromii. These biological insights provide promising avenues for treatment development.Competing Interest StatementDr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, Clearmind Medicine, and Altimmune; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; and a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics; Drs. Gelernter and Kranzler hold U.S. patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists,” issued 26 January 2021.Funding StatementVeterans Integrated Service Network 4, Mental Illness Research, Education and Clinical Center, National Institute on Alcohol Abuse and Alcoholism grants R01 AA030056 and K01 AA028292 (to RLK), and National Human Genome Research Institute grant T32 HG009495 (to KLF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Penn Medicine BioBank received ethical approval for this work under IRB protocol no. 813913. The VUMC Institutional Review Board oversees BioVU and approved this project (IRB #160302, #172020, #190418).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesGWAS Summary Statistics used for the present study can be accessed at the following locations: UK Biobank (http://www.nealelab.is/uk-biobank/), dbGaP accession phs001672 for Million Veteran Program (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001672), European Bioinformatics Institute GWAS Catalog (https://www.ebi.ac.uk/gwas/) under accession number GCST90016564. Once accepted for publication, summary statistics for the somatoform factor will be made publicly available.